Alpha Cognition To Present New Clinical Data On Cholinesterase Inhibitors And Its Investigational Therapy Zunveyl At American Society Of Consultant Pharmacists Annual Meeting, October 23–25, 2025.

Author: Benzinga Newsdesk | October 06, 2025 07:34am

Alpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.

On October 24, the Company will present:

• Poster 12: Acetylcholinesterase Inhibitors and Psychotropic Medication Use in ADRD
• Poster 3: Persistence of Therapy in ADRD
• Poster 4: Evidence-Based Approaches to Switching AChEIs in Alzheimer's Disease

"It has been more than three decades since cholinesterase inhibitors were introduced and a decade since the last went generic. Much of the product-specific knowledge has been lost," said Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition. "With ZUNVEYL, it is important to re-examine these treatments and provide renewed, evidence-based guidance for clinicians, patients, and families."

Posted In: ACOG